Skip to content
Hemispherx Biopharma, Inc. Logo
  • COMPANY
  • PRODUCTS
  • R & D
    • Product Candidates Overview
    • Pipeline
    • Orphan Drug Designations
  • PARTNERING
  • INVESTOR RELATIONS
    • Press Releases
    • Events & Presentations
    • Stock Information
    • SEC Filings
    • XBRL Filings
    • Stockholder Meeting
    • Corporate Governance
    • Email Alerts
    • Investor Contact
  • BLOG
  • CONTACT

Press Releases

 
Mar 09, 2022
AIM ImmunoTech Announces Abstracts from Roswell Park Comprehensive Cancer Center Accepted for Presentation in a Late-Breaking Poster Session at the AACR 2022 Annual Meeting

Mar 08, 2022
AIM ImmunoTech Announces Publication of Positive Data from Late-Stage Pancreatic Cancer Early Access Program (EAP) in the Cancers Special Issue: Combination and Innovative Therapies for Pancreatic Cancer

Mar 07, 2022
AIM ImmunoTech Announces Strategic Sale of New Brunswick, New Jersey Facility to Allocate Additional Resources to Advance Pipeline

Mar 03, 2022
AIM ImmunoTech Appoints Robert Dickey, IV as Chief Financial Officer

Jan 26, 2022
AIM ImmunoTech to Participate in a Solve M.E. Diagnostics and Treatments Webinar

Jan 24, 2022
AIM ImmunoTech Announces Publication of Positive Results from Phase 1/2 Study of Intraperitoneal Chemo-Immunotherapy in Advanced Recurrent Ovarian Cancer

Jan 19, 2022
AIM ImmunoTech to Present at the Virtual Investor 2022 Top Picks Conference

Dec 09, 2021
AIM ImmunoTech's Ampligen Safety Data Presented at Eighth European Scientific Working Group on Influenza

Dec 06, 2021
AIM ImmunoTech CEO to Participate in Two Upcoming Investor Conferences

Nov 16, 2021
AIM ImmunoTech Provides Third Quarter 2021 Business Update

 1   2     3    4   5   6   7   8 
 <<   <   >   >> 
Hemispherx Biopharma, Inc. Logo White

Latest News

  • CEO Roadshow Interviews Hemispherx Thomas K. Equels
  • Introducing You to the First Ampligen Quarterly Update
  • Proactive Investors USA Sits Down with Hemispherx CEO Thomas K. Equels

Privacy / Terms of Use

  • Terms Of Use
  • Investor Contact

Tweets by AIM Immuno

© Copyright | All Rights Reserved | AIM ImmunoTech Inc. | Privacy Policy | Terms of Use
FacebookTwitterYouTubeLinkedIn

Privacy
Resize Viewer - Reduce Resize Viewer - Expand Close window